Biotech Values

[BTH]

IV formulation versus Oral

Is there any benefit of having an oncology drug (not immunotherapy) run through a couple years worth of trials, Phase 1 exploratory, in an IV formula, only to have the very same drug being developed in an oral formula which will then hae to be submitted as an IND and run through more trials to see if it matches the results of the IV formula?

I can see this happening ten years ago when many drugs were IV, but is this still common today, for new, IND-phase 1 drugs? Is there something to this or is this just a case of incompetence/piss-poor planning and/or a money issue?

TIA